Galderma Group AG (CHIX:GALDZ) Cash, Cash Equivalents, Marketable Securities : CHF407 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Galderma Group AG Cash, Cash Equivalents, Marketable Securities?

Galderma Group AG's quarterly cash, cash equivalents, marketable securities increased from Dec. 2023 (CHF318.25 Mil) to Jun. 2024 (CHF344.11 Mil) and increased from Jun. 2024 (CHF344.11 Mil) to Dec. 2024 (CHF407.46 Mil).

Galderma Group AG's annual cash, cash equivalents, marketable securities increased from . 20 (CHF0.00 Mil) to Dec. 2023 (CHF318.25 Mil) and increased from Dec. 2023 (CHF318.25 Mil) to Dec. 2024 (CHF407.46 Mil).

Galderma Group AG Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Galderma Group AG's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galderma Group AG Cash, Cash Equivalents, Marketable Securities Chart

Galderma Group AG Annual Data

Trend

Dec23

Dec24

Cash, Cash Equivalents, Marketable Securities

318.25

407.46

Galderma Group AG Semi-Annual Data
	Jun23	Dec23	Jun24	Dec24
Cash, Cash Equivalents, Marketable Securities	-	318.25	344.11	407.46

Galderma Group AG Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Galderma Group AG (CHIX:GALDz) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Galderma Group AG Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Galderma Group AG's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Galderma Group AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Galderma Group AG (CHIX:GALDz) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

GALDY:USA GDERF:USA PY3:Germany GALD:Switzerland

Address

Zahlerweg 10, Zug, CHE, 6300

Website

https://www.galderma.com

Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a standalone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 45% of net sales from the US and employs around 6,600 people.

Galderma Group AG Headlines

No Headlines